Clinical Trial Update: T Cells Expressing Fully-human Anti-CD19 and Anti-CD20 Chimeric Antigen Receptors for Treating B-cell Malignancies and Hodgkin Lymphoma [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating T cells engineered with fully-human anti-CD19 and anti-CD20 CARs for B-cell malignancies and Hodgkin lymphoma; the study is terminated …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Chronic Lymphocytic Leukemia
• B-cell Lymphoma
• Chronic Lymphocytic Leukemia
• Hodgkin Lymphoma
• Non-hodgkin Lymphoma

Drugs mentioned

• CAR-T cells targeting CD19 and CD20 (anti-CD19 and anti-CD20 chimeric antigen receptor T cells)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Lymphoma, B-Cell, Lymphoma, Non-hodgkins | Phase 1 | Status: TERMINATED | Results posted: 2022-02-15